Cargando…
Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage
Renal fibrosis is a common pathological outcome of various chronic kidney diseases, and as yet, there is no specific treatment. Dapagliflozin has shown renal protection in some clinical trials as a glucose-lowering drug, but its role and mechanism on renal fibrosis remain unclear. In this study, we...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028454/ https://www.ncbi.nlm.nih.gov/pubmed/36959860 http://dx.doi.org/10.3389/fphar.2023.1095487 |
_version_ | 1784909949335240704 |
---|---|
author | Zeng, Jianhua Huang, Hao Zhang, Yan Lv, Xin Cheng, Jiawei Zou, Si Jue Han, Yuanyuan Wang, Songkai Gong, Li Peng, Zhangzhe |
author_facet | Zeng, Jianhua Huang, Hao Zhang, Yan Lv, Xin Cheng, Jiawei Zou, Si Jue Han, Yuanyuan Wang, Songkai Gong, Li Peng, Zhangzhe |
author_sort | Zeng, Jianhua |
collection | PubMed |
description | Renal fibrosis is a common pathological outcome of various chronic kidney diseases, and as yet, there is no specific treatment. Dapagliflozin has shown renal protection in some clinical trials as a glucose-lowering drug, but its role and mechanism on renal fibrosis remain unclear. In this study, we used a 0.2% adenine diet-induced renal fibrosis mouse model to investigate whether dapagliflozin could protect renal function and alleviate renal fibrosis in this animal model. In vivo, we found that dapagliflozin’s protective effect on renal fibrosis was associated with 1) sustaining mitochondrial integrity and respiratory chain complex expression, maintained the amount of mitochondria; 2) improving fatty acid oxidation level with increased expression of CPT1-α, PPAR-α, ACOX1, and ACOX2; 3) reducing inflammation and oxidative stress, likely via regulation of IL-1β, IL-6, TNF-α, MCP-1, cxcl-1 expression, and glutathione (GSH) activity, superoxide dismutase (SOD) and malondialdehyde (MDA) levels; and 4) inhibiting the activation of the TGF-β1/MAPK pathway. In HK2 cells treated with TGF-β1, dapagliflozin reduced the expression of FN and α-SMA, improved mitochondrial respiratory chain complex expression, and inhibited activation of the TGF-β1/MAPK pathway. |
format | Online Article Text |
id | pubmed-10028454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100284542023-03-22 Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage Zeng, Jianhua Huang, Hao Zhang, Yan Lv, Xin Cheng, Jiawei Zou, Si Jue Han, Yuanyuan Wang, Songkai Gong, Li Peng, Zhangzhe Front Pharmacol Pharmacology Renal fibrosis is a common pathological outcome of various chronic kidney diseases, and as yet, there is no specific treatment. Dapagliflozin has shown renal protection in some clinical trials as a glucose-lowering drug, but its role and mechanism on renal fibrosis remain unclear. In this study, we used a 0.2% adenine diet-induced renal fibrosis mouse model to investigate whether dapagliflozin could protect renal function and alleviate renal fibrosis in this animal model. In vivo, we found that dapagliflozin’s protective effect on renal fibrosis was associated with 1) sustaining mitochondrial integrity and respiratory chain complex expression, maintained the amount of mitochondria; 2) improving fatty acid oxidation level with increased expression of CPT1-α, PPAR-α, ACOX1, and ACOX2; 3) reducing inflammation and oxidative stress, likely via regulation of IL-1β, IL-6, TNF-α, MCP-1, cxcl-1 expression, and glutathione (GSH) activity, superoxide dismutase (SOD) and malondialdehyde (MDA) levels; and 4) inhibiting the activation of the TGF-β1/MAPK pathway. In HK2 cells treated with TGF-β1, dapagliflozin reduced the expression of FN and α-SMA, improved mitochondrial respiratory chain complex expression, and inhibited activation of the TGF-β1/MAPK pathway. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10028454/ /pubmed/36959860 http://dx.doi.org/10.3389/fphar.2023.1095487 Text en Copyright © 2023 Zeng, Huang, Zhang, Lv, Cheng, Zou, Han, Wang, Gong and Peng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zeng, Jianhua Huang, Hao Zhang, Yan Lv, Xin Cheng, Jiawei Zou, Si Jue Han, Yuanyuan Wang, Songkai Gong, Li Peng, Zhangzhe Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage |
title | Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage |
title_full | Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage |
title_fullStr | Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage |
title_full_unstemmed | Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage |
title_short | Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage |
title_sort | dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting tgf-β1/mapk mediated mitochondrial damage |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028454/ https://www.ncbi.nlm.nih.gov/pubmed/36959860 http://dx.doi.org/10.3389/fphar.2023.1095487 |
work_keys_str_mv | AT zengjianhua dapagliflozinalleviatesrenalfibrosisinamousemodelofadenineinducedrenalinjurybyinhibitingtgfb1mapkmediatedmitochondrialdamage AT huanghao dapagliflozinalleviatesrenalfibrosisinamousemodelofadenineinducedrenalinjurybyinhibitingtgfb1mapkmediatedmitochondrialdamage AT zhangyan dapagliflozinalleviatesrenalfibrosisinamousemodelofadenineinducedrenalinjurybyinhibitingtgfb1mapkmediatedmitochondrialdamage AT lvxin dapagliflozinalleviatesrenalfibrosisinamousemodelofadenineinducedrenalinjurybyinhibitingtgfb1mapkmediatedmitochondrialdamage AT chengjiawei dapagliflozinalleviatesrenalfibrosisinamousemodelofadenineinducedrenalinjurybyinhibitingtgfb1mapkmediatedmitochondrialdamage AT zousijue dapagliflozinalleviatesrenalfibrosisinamousemodelofadenineinducedrenalinjurybyinhibitingtgfb1mapkmediatedmitochondrialdamage AT hanyuanyuan dapagliflozinalleviatesrenalfibrosisinamousemodelofadenineinducedrenalinjurybyinhibitingtgfb1mapkmediatedmitochondrialdamage AT wangsongkai dapagliflozinalleviatesrenalfibrosisinamousemodelofadenineinducedrenalinjurybyinhibitingtgfb1mapkmediatedmitochondrialdamage AT gongli dapagliflozinalleviatesrenalfibrosisinamousemodelofadenineinducedrenalinjurybyinhibitingtgfb1mapkmediatedmitochondrialdamage AT pengzhangzhe dapagliflozinalleviatesrenalfibrosisinamousemodelofadenineinducedrenalinjurybyinhibitingtgfb1mapkmediatedmitochondrialdamage |